Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial

Research output: Contribution to journalJournal articleResearchpeer-review

Kamilla Woznica Miskowiak, Hannelore Ehrenreich, Ellen M Christensen, Lars Vedel Kessing, Maj Vinberg

OBJECTIVE: Available drug treatments for bipolar disorder fail to reverse patients' cognitive deficits. Erythropoietin has neurotrophic actions and aids neurocognitive function. The aim of the study was to investigate the potential of erythropoietin to treat cognitive dysfunction in bipolar disorder.

METHOD: Patients with an ICD-10 diagnosis of bipolar disorder in remission were randomized, with stratification by age and gender, to receive 8 weekly erythropoietin (40,000 IU) or saline (sodium chloride [NaCl], 0.9%) infusions in a double-blind, parallel-group design. The first patient was randomized in September 2009 and last assessment was completed in October 2012. Patients were assessed at baseline and at weeks 9 and 14. The primary outcome was change in verbal memory indexed by the total words recalled across Rey Auditory Verbal Learning Test learning trials (I-V) from baseline to week 9; secondary outcomes were sustained attention and facial expression recognition; and tertiary outcomes were attention, executive function, subjective cognitive function, and mood. Analysis was by intention to treat, using repeated-measures analysis of covariance adjusted for stratification variables and mood. The statistical threshold for which results were considered significant was P ≤ .05 (2-tailed).

RESULTS: 44 patients were randomized; given 1 dropout after baseline, results were analyzed for 43 patients (erythropoietin: n = 23; saline: n = 20). There was no significant improvement of verbal memory in erythropoietin versus saline groups (P = .10). However, erythropoietin enhanced sustained attention (P = .001), recognition of happy faces (P = .03), and speed of complex information processing across learning, attention, and executive function (P = .01). These effects occurred in absence of changes in simple reaction times or mood (P values ≥ .16) and were maintained after red blood cell normalization.

CONCLUSIONS: This is the first trial investigating erythropoietin to treat cognitive dysfunction in bipolar disorder. The findings highlight erythropoietin as a candidate treatment for deficits in attention and executive function in bipolar disorder.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00916552.

Original languageEnglish
JournalJournal of Clinical Psychiatry
Volume75
Issue number12
Pages (from-to)1347-1355
Number of pages9
ISSN0160-6689
DOIs
Publication statusPublished - Dec 2014

    Research areas

  • Adolescent, Adult, Aged, Attention, Bipolar Disorder, Cognition Disorders, Double-Blind Method, Erythropoietin, Executive Function, Female, Humans, Learning, Male, Mental Recall, Middle Aged, Reaction Time, Recognition (Psychology), Recombinant Proteins, Young Adult

ID: 137660477